|Videos|July 9, 2015

2015 World Congress on GI Cancer

Episodes in this series

Stay up to date on the most recent and practice-changing oncology data

August 11th, 2026

Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.

August 9th, 2026

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

August 19th, 2026

Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, being evaluated in pancreatic ductal adenocarcinoma.

August 19th, 2026

Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.

August 16th, 2026

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

August 15th, 2026

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

August 14th, 2026

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

August 14th, 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.